周五，热景生物股价20CM涨停，股价创下历史新高，最新总市值为180.6亿元。 自去年9月18日以来，热景生物股价累计涨超724.8%，最低触及22.94元/股，最高达194.81元/股。 | → 分时 ■ 周 月 季 年 1分 5分 15分 30分 60分 30s ▼ 多周期 设置 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 日线(复权) 热景生物 MA5: 160.15↑ MA10: 149.86↑ MA20: 148.87↑ MA30: 141.63↑ MA60: 129.14↑ | | | | | | | | 《 个股K线区间统计 | | | X | | | | | | | | | 起始时间: 2024-09-18 | | | 周期个数: | | | | | | | | | 终止时间: 2025-07-04 | | | 191个 | | | | | | | | | 起始价: | 23.62 | 终止价: | 194.81 | | | | | | | ...

证券分析师 张浩 资格编号：S0120524070001 邮箱：zhanghao3＠tebon.com.cn 研究助理 [Table_Main] 证券研究报告 | 宏观专题 2025 年 07 月 02 日 宏观专题 相关研究 德邦证券 7 月研判及金股 [Table_Summary] 投资要点： 宏观研判：攻守兼备、以逸待劳 德邦证券 2025 年 7 月金股组合 化工 卓越新能（688196.SH）：中国生物柴油工业化生产先驱；生物柴油紧平衡格局 延续，关注原料替代与贸易突围；反倾销危局催动全球布局，渠道自主重构破贸易壁 请务必阅读正文之后的信息披露和法律声明 副标题：楷体四号，非必填 当前影响整个市场的宏观变量主要是三个方面——内需修复进程、政策落地效果 和外部环境变化，眼下宏观领域的一系列分歧本质上是对这三方面宏观变量存在 不同的假设和推演，我们认为资产配置要攻守兼备、以逸待劳，在不确定性中寻找 确定性，把握趋势并做好应对。 一、外部环境方面，中美关税谈判的缓和有助于缓释基本面及市场风险偏好的压 力，中长期中美关系依旧处于一个竞争高于合作的阶段，特朗普政府依旧将"去风 险化"作为重要战略方向，这意味着 ...

证券研究报告 | 宏观专题 2025年07月02日 德邦证券7月研判及金股 宏观专题 投资要点: 资格编号: S0120524070001 预期. 后者则是立足绝对收益思维,建议关注铜、铝、稀土、锡等;债券:预计利 率债低位震荡概率较高。信用利差已处于历史级"低位",建议关注类债资产与转 债机会。 · 德邦证券 2025年7月金股组合 化工 卓越新能(688196.SH):中国生物柴油工业化生产先驱;生物柴油紧平衡格局 延续,关注原料替代与贸易突围;反倾销危局催动全球布局,渠道自主重构破贸易壁 请务必阔读正文之后的信息披露和法律声明 证券分析师 张浩 邮箱:zhanghao3@tebon.com.cn 研究助理 相关研究 · 宏观研判:攻守兼备、以逸待劳 ● 当前影响整个市场的宏观变量主要是三个方面 -- 内需修复进程、政策落地效果 和外部环境变化,眼下宏观领域的一系列分歧本质上是对这三方面宏观变量存在 不同的假设和推演,我们认为资产配置要攻守兼备、以逸待劳,在不确定性中寻找 确定性,把握趋势并做好应对。 ● 一、外部环境方面,中美关税谈判的缓和有助于缓释基本面及市场风险偏好的压 力,中长期中美关系依旧处于一 ...

Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].

Core Viewpoint - The second largest shareholder of Hotgen Biotech, Zhou Xin, plans to reduce his stake in the company after a significant increase in stock price, indicating potential liquidity needs and market volatility [2][5]. Shareholder Actions - Zhou Xin intends to sell up to 1.8 million shares, representing approximately 1.94% of the total share capital, to meet personal funding requirements [2]. - As of the announcement date, Zhou Xin holds 6.8066 million shares, accounting for 7.342% of the total shares [3]. Financial Performance - In 2024, Hotgen Biotech reported a revenue of 511 million yuan, a year-on-year decrease of 6.74%, and a net loss of 191 million yuan, a significant decline of 760.4% [7]. - The company experienced a surge in performance during the COVID-19 pandemic in 2021, but both revenue and stock price have since declined sharply [6]. Historical Cashing Out - Prior to the current planned reduction, Zhou Xin has already cashed out approximately 2.1 billion yuan from his holdings in Hotgen Biotech since its IPO [4]. - His previous cashing out included approximately 21.59 million yuan in 2017 and 65.59 million yuan in 2018, totaling around 87.17 million yuan over those two years [4]. Market Context - Hotgen Biotech's stock price has seen a dramatic increase of over 6 times since late September 2024, similar to a previous surge of 5 times in April 2021 [5]. - As of June 25, 2024, the stock closed at 137.2 yuan per share, giving the company a market capitalization of 12.7 billion yuan [11]. Strategic Developments - The company is focusing on innovative biopharmaceutical technologies through its "Future Technology Research Institute," with strategic investments in companies developing cutting-edge antibody and nucleic acid drugs [11].

【导读】热景生物第二大股东拟减持不超过180万股公司股份 中国基金报记者 卢鸰 在股价暴涨超6倍后，热景生物第二大股东周锌又要减持。此前，在周锌于2021年7月减持前，热景生物股价在 当年 4月曾 一 月暴涨5 倍。 据热景生物6月25日晚公告，公司近日收到股东周锌发出的《关于减持公司股份的告知函》。因自身资金需求，股东周锌计划通过集中竞 价、大宗交易方式减持所持公司股份合计不超过180万股，占公司总股本的1.9416%。 以热景生物6月25日的收盘价估算，此次减持周锌将最 多 套现约2.5亿元。 总计 已 套现约2.1亿元 2019年9月热景生物在科创板上市时，周锌所持股份占比为10.35%，是公司第二大股东。 截至公告披露日，周锌仍为热景生物第二大股东，持有公司股份680.66万股，占公司股份总数的7.342% 。其 股份来源于公司首次公开发 行前持有及资本公积转增股本取得，已上市流通。 据招股书披露，通过协议转让方式，在上市前的2017年，周锌曾套现约2158.89万元，2018年又套现约6558.82万元，两年总计套现约 8717.71万元。 根据Wind数据，上市之后，通过二级市场，周锌已减持套现约 ...

以下文章来源于调兵投资 ，作者userfield 调兵投资 . userfield，田野 风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者：userfield 来源：雪球 赚钱容易，是因为2025年医药板块投资主线很清晰——就是创新药，更聚焦的说法是有出海预期 的创新药。一旦有了清晰主线，大家都知道啥票会涨，或者说复盘的时候，上涨股票有非常清晰 的特征。 但不简单：行情走到现在，该涨的都已经涨了一大波，向上空间完全看市场情绪。而轮动上涨的 创新药"边角料"，可能热点又转换很快。所以现在选股又不简单，需要判断行情、把握热点、快 速操作，赚创新药行情钱的难度上了一个台阶。 二、25年初至今涨幅的量化统计 30/50：涨幅超过30%的票差不多有50多支，而其中与创新药相关的股票差不多30多支，也就是说 今年大涨票与创新药的相关系数非常明显。 35%：创新药资产（标签化明显）大约50支票，平均涨幅是50%，中位数涨幅是35%。 三、高弹性股票的创新药逻辑 我们看看涨幅大的票，相关创新药靶点特点以及对股票的弹性。 1、舒泰神：凝血因子X 激活剂。舒泰神的股价启动比较晚。25年4 ...

Group 1: Financing and Investment - ShunJing Pharmaceutical has completed a 300 million RMB Series A financing round, led by multiple investment firms including Songhe Fund and Dacheng Fund [1] - The funds will primarily be used to accelerate the Phase II clinical trials of SGC001, a novel antibody drug for acute myocardial infarction, and other core pipeline IND applications and clinical research [1] - Horizon Robotics has announced a successful 100 million USD Series A financing round, attracting numerous domestic and international investors [2] Group 2: Product Development and Innovation - ShunJing Pharmaceutical focuses on developing first-in-class (FIC) and best-in-class (BIC) drugs, with SGC001 being the fastest in development, having received IND approval from both the FDA and the National Medical Products Administration [1] - The company aims to enhance its strategic layout in the biopharmaceutical industry, aligning with China's 14th Five-Year Plan for biopharmaceutical development [1] - Horizon Robotics has built a complete product system covering chips, algorithms, and software to meet the diverse needs of intelligent robots across various sectors [3] Group 3: Market Expansion and Ecosystem - ShunJing Pharmaceutical's funding is expected to deepen its strategic layout and enhance its long-term operational development [1] - Horizon Robotics is expanding its developer ecosystem, empowering over 200 small and medium-sized creators and incubating nearly 100 new types of intelligent robots [5] - The company has established partnerships with over 200 universities to cultivate talent in the field of intelligent robotics [6] Group 4: Industry Trends and Future Outlook - The financing activities reflect a growing interest in the biopharmaceutical and intelligent robotics sectors, indicating a robust investment climate [2][4] - Companies are increasingly focusing on integrating innovative technologies and expanding their product offerings to capture larger market shares [2][5] - The advancements in intelligent robotics and biopharmaceuticals are expected to contribute significantly to the overall growth of the respective industries in the coming years [1][3]

完整早报音频，请点击标题下方小耳机收听 【百度起诉小米， 6 月 13 日开庭】 北京百度网讯科技有限公司与小米科技有限责任公司、上海宜谊信息科技有限 公司相关的不正当竞争纠纷案件新增开庭公告，该案件将于 6 月 13 日在上海市青浦区人民法院开庭审理。据了 解，北京百度网讯科技有限公司起诉上述两家公司的案由都是"不正当竞争纠纷"，案件原告都是北京百度网讯科技 有限公司。截至发稿前，百度和小米双方均未回应。（东方财富网） | 法院 | 法庭 | | --- | --- | | 上海市青浦区人民法院 | 西虹桥第二法反 | | 承办部门 | 审判长/主审长 | | 西虹桥(进口博览会) 人民 | 章晓琴 | | 法庭 | | | 开庭时间 | 排期日期 | | 2025-06-13 09:00 | | | 1 开庭提醒, | | 【余承东：一个拳头有五个手指，华为将只有五个 "界"】 在 2025 （第三届）未来汽车先行者大会上，华为常务 董事、终端 BG 董事长余承东透露，华为将只做五个"界"。他表示，"上次聚首的时候，我们认为还只有四界，结 果后来发生了很多的变化，在贾总和各位领导强力的推动下，我们又增加了 ...

5月22日，热景生物（688068.SH）召开2024年年度股东大会，根据上交所信息披露，会议就董事及高管薪酬议案、2024年 度财务决算报告、利润分配预案等进行了表决。 就在股东大会召开的前两天，北京热景生物发布关于股东权益变动触及1%刻度的提示性公告，公司的控股股东/实控人的一 致行动人青岛同程热景企业管理咨询合伙企业（有限合伙）（简称"青岛同程"）于2025年5月16日通过集中竞价减持，股东 权益合计比例从28.00%减少到26.99%，本次权益变动属于股东减持股份，不触及要约收购。 股价与业绩背离 有投资者称，这是一家靠卖试剂撑起新药研发的公司。该公司利用入股创新药企的做法，迎来了一波行情。曲线图显示， 热景生物股价从2024年最低点的22.94元/股，一路狂飙，今年还一度高达142元/股，暴涨了550%，股价实现了超五倍的增 长。让投资者意外的是，在IVD行业节节败退的当下，热景生物业绩下滑，股价却因为参股创新药概念而大涨，其动态市 盈率一度远超万孚生物、九安医疗等IVD同行。 具体来看，热景生物的重要战略参股公司舜景医药聚焦原始创新 FIC（First-In-Class）抗体药物的研发，其开发的 ...